Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The hepatocyte growth factor/MET pathway has been shown to cause tumor progression in several types of carcinomas.
|
22198430 |
2012 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
RNA was extracted from histologically confirmed tumor isolates, and using real-time polymerase chain reaction (PCR) studies, we assessed the quantitative expression of 12 genes with potential importance in chemotherapy resistance and tumor progression, including thymidylate synthase (TS; 5-fluorouracil), excision repair cross complementing gene-1, and xeroderma pigmentosum groups A through G (oxaliplatin), topoisomerase-I (irinotecan), c-met, and hepatocyte growth factor.
|
21982065 |
2012 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of c-Met was detected in the tumor cells of 52% (80/153) of the patients and expression of its ligand, hepatocyte growth factor, in 8% (10/121) of the patients. c-Met expression correlated with a 5-year freedom from tumor progression of 94%, whereas lack of expression correlated with a 5-year freedom from tumor progression of 73% (P<0.001) in the combined cohort.
|
22180430 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that HGF/c-Met might exert their effects in tumor progression in association with RhoA and probably with TIMP-3.
|
21779788 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Because PC-3 cells were responsive to BMS-777607 but not the anti-HGF antibody, the findings also indicate that under circumstances where c-Met is constitutively hyperactive in the absence of functional HGF, targeting the c-Met receptor remains a viable therapeutic option to impede cancer progression.
|
22639908 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These new areas of research will help to uncover novel therapeutic targets to block the HGF/Met signaling axis to slow cancer progression.
|
21190524 |
2011 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hepatocyte growth factor (HGF) is associated with tumour progression and increases the invasiveness of prostate carcinoma cells.
|
20406887 |
2010 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The involvement of HGF in other aspects of tumor progression, such as invasion and metastasis, and novel downstream target genes activated by HGF is summarized next.
|
18781954 |
2008 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of hepatocyte growth factor (HGF) and c-Met is associated with tumor progression in many human malignancies.
|
18355439 |
2008 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These data show that proteolytic activation of pro-SF is a limiting step in tumor progression, thus suggesting a new strategy for the treatment or prevention of the malignant conversion of neoplastic lesions.
|
15545993 |
2004 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We used an experimental in vitro model of human ovarian surface epithelium (OSE), the tissue of origin of >90% of ovarian cancers, to more precisely define the contribution of hepatocyte growth factor (HGF) to various OSE phenotypes at different stages of neoplastic progression.
|
15302591 |
2004 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of both hepatocyte growth factor (HGF) and its tyrosine kinase receptor met has been demonstrated in normal tissues and their neoplastic counterparts, implicating these factors in normal development and tumour progression.
|
11748645 |
2002 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The elevation of circulating hepatocyte growth factor (HGF) concentrations is associated with tumor progression and prognosis in cancer patients.
|
11501846 |
2001 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here we show that beta-catenin activates the human laminin-5 gamma2 gene through two T-cell factor-binding elements in a synergistic manner together with hepatocyte growth factor and conclude that laminin-5 gamma2 is another important target gene of nuclear beta-catenin during tumor progression.
|
11719433 |
2001 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hepatocyte growth factor (HGF) is a multifunctional cytokine which is believed to have important roles in tissue development and regeneration, and tumor progression.
|
10202187 |
1999 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that targeting the SF/HGF-c-met signaling pathway may be an important approach in controlling tumor progression.
|
10491431 |
1999 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Aberrant expression of HGF/SF or c-met may play a role in tumour progression.
|
8837300 |
1996 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The tumor explants display increased hepatocyte growth factor/scatter factor expression and Met turnover, indicating that autocrine Met activation contributes to tumor progression.
|
7728766 |
1995 |